Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 26:36:e1731.
doi: 10.1590/0102-672020230002e1731. eCollection 2023.

INTRAGASTRIC BALLOON AND IMPACT ON WEIGHT LOSS: EXPERIENCE IN QUITO, EQUADOR

Jonathan Jerez  1 , David Cabrera  1 , Carlos Cisneros  1 , Monica Moreno  1 , Daniela Guaitara  1 , Chiristian Benavides  1 , Martha Fors  2 , Kirsten Falcon  3
Affiliations

INTRAGASTRIC BALLOON AND IMPACT ON WEIGHT LOSS: EXPERIENCE IN QUITO, EQUADOR

Jonathan Jerez et al. Arq Bras Cir Dig. .

Abstract
in English, Portuguese

Background: Obesity is associated with different medical conditions, such as cardiologic, respiratory, gastrointestinal, and genitourinary, and constitutes a severe health problem.

Aims: This study aimed to evaluate the use of intragastric fluid-filled balloon in the reduction of weight and other measurements related to body composition.

Methods: This is a retrospective, monocentric study involving all patients who opted for the intragastric balloon Spatz® placement from January 2018 to July 2019, with fulfillment of inclusion and exclusion criteria. The patients were analyzed after 6 and 12 months after the intragastric fluid-filled balloon placed.

Results: A total of 121 subjects were included in this study, with 83 (68.6%) females and 38 (31.4%) males. The mean age was 36 years and height was 1.64±0.09. Weight mean and standard deviation was 89.85±14.65 kg, and body mass index was 33.05±4.03; body mass index decreased to 29.4 kg/m2 with a mean weight of 79.83 kg, after 12 months of follow-up. There were statistical differences between body mass index and the 12 months in fat percentage, fat-free mass (kg), visceral fat area, and basal metabolic rate. There was a significant variation according to gender, with males having highest reduction. The percentage of excess weight loss was 46.19, and the total weight loss was 9.24 at the end of the study.

Conclusions: The study demonstrated a benefit of intragastric fluid-filled balloon on weight loss after 12 months. At the end of treatment, body mass index and the measurements of body composition were significantly lower. Men benefited more than women from the treatment.

RACIONAL:: A obesidade está associada a diferentes condições médicas, tais como cardiológicas, respiratórias, gastrointestinais, geniturinárias entre outras e constituem um grave problema de saúde.

OBJETIVOS:: Avaliar o emprêgo do balão intragástrico na redução de peso e em outras medidas relacionadas à composição corporal.

MÉTODOS:: Estudo retrospectivo, monocêntrico, incluindo todos os pacientes que optaram pela colocação de balão intragástrico Spatz® entre janeiro de 2018 e julho de 2019, com cumprimento dos critérios de inclusão e exclusão.

RESULTADOS:: Cento e vinte e um indivíduos foram recrutados neste estudo. A média de idade foi de 36 anos e estatura de 1,64±0,09, sendo 83 (68,6%) do sexo feminino e 38 (31,4%) do sexo masculino. A média do peso e o desvio padrão foram de 89,85±14,65 kg e o índice de massa corporal foi de 33,05±4,03. Após 12 meses, o índice de massa corporal diminuiu para 29,4 kg/m2 com um peso médio de 79,83 kg. Foram registradas diferenças estatísticas no índice de massa corporal, no percentual de gordura, massa livre de gordura (kg), área de gordura visceral e taxa metabólica basal. Houve variação significativa de acordo com o sexo, sendo o masculino com maior redução. O porcentual de perda de excesso de peso foi de 46,19% e de perda de peso total de 9,24 %ao final do estudo.

CONCLUSÕES:: O estudo demonstrou benefícios do balão intragástrico na perda de peso após 12 meses de colocação do balão. Ao final do tratamento, o índice de massa corporal e as medidas de composição corporal foram significativamente menores. Os homens se beneficiaram mais do que as mulheres do tratamento.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None

Figures

Figure 1A
Figure 1A. Baseline and final weight (kg).
Figure 1B
Figure 1B. Baseline and final BMI (kg/m2).
Figure 1C
Figure 1C. Baseline and final percentage fat mass (%).
Figure 1D
Figure 1D. Baseline and final fat-free mass (kg).
Figure 1E
Figure 1E. Baseline and final basal metabolic rate (kcal).
Figure 1F
Figure 1F. Baseline and final visceral fat area (cm2).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abu Dayyeh BK, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology. 2017;152(4):716–729. doi: 10.1053/j.gastro.2017.01.035. - DOI - PubMed
    1. Agnihotri A, Xie A, Bartalos C, Kushnir V, Islam S, Islam E, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16(7):1081–1088. doi: 10.1016/j.cgh.2018.02.026. - DOI - PubMed
    1. Al-Sabah S, Al-Ghareeb F, Ali DA, Al-Adwani A. Efficacy of intragastric balloon for the management of obesity: experience from Kuwait. Surg Endosc. 2016;30(2):424–429. doi: 10.1007/s00464-015-4212-z. - DOI - PubMed
    1. Al-Subaie S, Khalifa S, Buhaimed W, Al-Rashidi S. A prospective pilot study of the efficacy and safety of Elipse intragastric balloon: a single-center, single-surgeon experience. Int J Surg. 2017;48:16–22. doi: 10.1016/j.ijsu.2017.10.001. - DOI - PubMed
    1. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, et al. Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–438.:e5. doi: 10.1016/j.gie.2015.03.1964. - DOI - PubMed